menjugate 10 micrograms suspension for injection meningococcal group c conjugate vaccine
gsk vaccines s.r.l. - meningococcal group c oligosaccharide; corynebacterium diphtheriae crm197 protein - suspension for injection in pre-filled syringe - 10 - meningococcal vaccines; other meningococcal polyvalent purified polysaccharides antigen - meningococcal vaccines - active immunisation of children from 2 months of age, adolescents and adults, for the prevention of invasive disease caused by neisseria meningitidis group c.
amlodipine/valsartan novartis10/320 amlodipine 10 mg/valsartan 320 mg film-coated tablet blister pack
novartis pharmaceuticals australia pty ltd - amlodipine besilate, quantity: 13.87 mg (equivalent: amlodipine, qty 10 mg); valsartan, quantity: 320 mg - tablet, film coated - excipient ingredients: crospovidone; colloidal anhydrous silica; sodium starch glycollate; microcrystalline cellulose; magnesium stearate; iron oxide yellow; titanium dioxide; hypromellose; purified talc; macrogol 4000 - amlodipine/valsartan novartis is indicated for the treatment of hypertension. treatment should not be initiated with this fixed dose combination.
amlodipine/valsartan novartis 5/320 amlodipine 5 mg/valsartan 320 mg film-coated tablet blister pack
novartis pharmaceuticals australia pty ltd - amlodipine besilate, quantity: 6.94 mg (equivalent: amlodipine, qty 5 mg); valsartan, quantity: 320 mg - tablet, film coated - excipient ingredients: crospovidone; sodium starch glycollate; iron oxide yellow; colloidal anhydrous silica; magnesium stearate; microcrystalline cellulose; hypromellose; purified talc; iron oxide red; macrogol 4000 - amlodipine/valsartan novartis is indicated for the treatment of hypertension. treatment should not be initiated with this fixed dose combination.
amlodipine/valsartan novartis 10/160 amlodipine 10 mg/valsartan 160 mg film-coated tablet blister pack
novartis pharmaceuticals australia pty ltd - amlodipine besilate, quantity: 13.87 mg (equivalent: amlodipine, qty 10 mg); valsartan, quantity: 160 mg - tablet, film coated - excipient ingredients: magnesium stearate; microcrystalline cellulose; colloidal anhydrous silica; crospovidone; titanium dioxide; hypromellose; purified talc; macrogol 4000; iron oxide red; iron oxide yellow - amlodipine/valsartan novartis is indicated for the treatment of hypertension. treatment should not be initiated with this fixed dose combination.
amlodipine/valsartan novartis 5/160 amlodipine 5 mg/valsartan 160 mg film-coated tablets blister pack
novartis pharmaceuticals australia pty ltd - valsartan, quantity: 160 mg; amlodipine besilate, quantity: 6.94 mg (equivalent: amlodipine, qty 5 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; crospovidone; magnesium stearate; colloidal anhydrous silica; hypromellose; purified talc; iron oxide yellow; macrogol 4000; titanium dioxide - amlodipine/valsartan novartis is indicated for the treatment of hypertension. treatment should not be initiated with this fixed dose combination.
infanrix penta
glaxosmithkline biologicals s.a. - diphtheria toxoid, tetanus toxoid, bordetella pertussis antigens (pertussis toxoid, filamentous haemagglutinin, pertactin), poliovirus (inactivated) (type 1 (mahoney strain), type 2 (mef-1 strain), type 3 (saukett strain)), hepatitis b surface antigen - hepatitis b; tetanus; immunization; whooping cough; poliomyelitis; diphtheria - vaccines - infanrix penta is indicated for primary and booster vaccination of infants against diphtheria, tetanus, pertussis, hepatitis b and poliomyelitis.
prexige
novartis new zealand ltd - lumiracoxib 100mg (release testing to occur at novartis ag, lichstrasse, basel.) - film coated tablet - 100 mg - active: lumiracoxib 100mg (release testing to occur at novartis ag, lichstrasse, basel.) excipient: croscarmellose sodium lactose monohydrate magnesium stearate microcrystalline cellulose opadry opadry white 00f18296 povidone titanium dioxide
prexige
novartis new zealand ltd - lumiracoxib 200mg (release testing to occur at novartis ag, lichstrasse, basel.) - film coated tablet - 200 mg - active: lumiracoxib 200mg (release testing to occur at novartis ag, lichstrasse, basel.) excipient: croscarmellose sodium lactose monohydrate magnesium stearate microcrystalline cellulose opadry black 00f17713 opadry red 00f15613 opadry white 00f18296 povidone titanium dioxide
prexige
novartis new zealand ltd - lumiracoxib 400mg (release testing to occur at novartis ag, lichstrasse, basel.) - film coated tablet - 400 mg - active: lumiracoxib 400mg (release testing to occur at novartis ag, lichstrasse, basel.) excipient: croscarmellose sodium 00f17713 basic coating premix black magnesium stearate microcrystalline cellulose opadry opadry white 00f18296 povidone
novartis octreotide lar octreotide (as acetate) 30 mg modified release injection vial plus diluent prefilled syringe composite p
novartis pharmaceuticals australia pty ltd - octreotide -